Trius Confident After Phase II Results For Skin Infections, Including MRSA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Trius Therapeutics is headed into Phase III for its lead antibiotic candidate torezolid (TR-701) with an important advantage over other sponsors that have tried for a complicated skin and skin structure claim in the past year: Trius has a clear sense of the outcome FDA now expects to see in a noninferiority study.
You may also be interested in...
Telavancin’s “Complete Response” Letter Calls For Pregnancy-Focused REMS
After a three-day, three-drug advisory committee in November, the last sponsor standing - or at least the last to get a "complete response" letter from FDA - may be in the best position to move forward with its complicated skin and skin structure infections antibiotic
FDA Updating Antibiotic Guidances, But Is It Too Late For Some Sponsors?
It was supposed to be a year with a wealth of novel antibiotics, but regulatory concerns turned 2008 from a year of banner antibiotic approvals into a sizeable crop of action letters. Now the delays are taking a serious toll, causing some sponsors to drastically restructure in the face of uncertain and evolving regulatory standards
Industry’s Lesson On Non-Inferiority Margins In Anti-Infective Trials: Use 10%
If industry is to learn anything from the three-day Anti-Infective Drugs Advisory Committee meeting on how to correctly use non-inferiority margins in trials, it is to adhere to the panel's recommendation of 10 percent (at least for now)